# US 2020/0390753 A1 · Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390753 A1
- Document ID: US20200390753A1
- Status: Published application
- Kind: A1
- Application number: 16/710,103
- Filed: 2019-12-11
- Published: 2020-12-17
- Earliest claimed: 2015-03-20
- Assignees: Poxel
- Applicants: Poxel SA
- Inventors: Sheila DeWitt; Vincent Jacques; Leonardus van der Ploeg
- Web page: https://patentgrep.com/patent/US20200390753A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.

## Claims

### Claim at position 1

1-50. (canceled)

### Claim 51

A method of treating nonalcoholic steatohepatitis, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the nonalcoholic steatohepatitis; wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof, wherein:
A1, A2, A3, and A4 are independently —C(R9)(R10)—;
A5 is —C(R11)(R12)(R13);
R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D; and
Z is H or D, provided that the abundance of deuterium in Z is at least 30%; and
the second therapeutic agent comprises pentoxifylline, metformin, obeticholic acid, simtuzumab, aramchol, GFT-505 ((E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid), IMM-124E (bovine colostrum powder, harvested from cows immunized with lipopolysaccharide vaccine), cenicriviroc, metreleptin, sitagliptin, GR-MD-02 (compound developed by Galectin), SHP626 (compound developed by Shire), or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 51)

The method of claim 51, wherein the second therapeutic agent comprises pentoxifylline, or metformin.

### Claim 53

A method of treating a diabetes selected from the group consisting of Type I diabetes mellitus and Type II diabetes mellitus, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the diabetes; wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof, wherein:
A1, A2, A3, and A4 are independently —C(R9)(R10)—;
A5 is —C(R11)(R12)(R13);
R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D; and
Z is H or D, provided that the abundance of deuterium in Z is at least 30%; and
the second therapeutic agent comprises metformin, a dipeptidyl peptidase IV inhibitor, a statin, an agonist of glucagon-like peptide-1, an agonist of glucagon-like peptide-2, an inhibitor of sodium/glucose cotransporter 2, insulin, an insulin analog, a GRP40 agonist, an alpha-glucosidase inhibitor, an incretin, an anti-hypertensive agent, pramlintide, benfluorex, leptin, glyburide, gliclazide, glimepiride, glipizide, tolbutamide, tolazamide, chlorpropamide, nateglinide, repaglinide, mitiglinide, or a pharmaceutically acceptable salt thereof.

### Claim 54

A method selected from:
(a) a method of treating nonalcoholic fatty liver disease, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the nonalcoholic fatty liver disease; wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof, wherein:
A1, A2, A3, and A4 are independently —C(R9)(R10)—;
A5 is —C(R11)(R12)(R13);
R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D; and
Z is H or D, provided that the abundance of deuterium in Z is at least 30%; and
the second therapeutic agent comprises saroglitazar, vitamin D, cysteamine bitartrate, IDN-6556, losartan, sitagliptin, docosahexaenoic acid, eicosapentaenoic acid, pradigastat, berberine, an omega 3 fatty acid ester, resveratrol, Px-104, vitamin E, RO5093151, liraglutide, insulin glargine, lobeglitazone, oltipraz, S-adenosyl-L-methionine, amlexanox, rifampicin, pitavastatin, or a pharmaceutically acceptable salt thereof;
(b) a method of treating a fibrotic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the fibrotic disorder; wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof, wherein:
A1, A2, A3, and A4 are independently —C(R9)(R10)—;
A5 is —C(R11)(R12)(R13);
R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D; and
Z is H or D, provided that the abundance of deuterium in Z is at least 30%; and
the second therapeutic agent comprises entecavir, IDN-6556, DCB-BO1202, FG-3019, ND-L02-s0201, docosahexaenoic acid, Vitamin E, choline, cenicriviroc, GR-MD-02, raltegravir, rifaximin, S-adenosylmethionine, tenofovir disoproxil fumarate, emtricitabine, adefovir dipivoxil, pentoxifylline, simtuzumab, or a pharmaceutically acceptable salt thereof;
(c) a method of treating liver cancer, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the liver cancer; wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof, wherein:
A1, A2, A3, and A4 are independently —C(R9)(R10)—;
A5 is —C(R11)(R12)(R13);
R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D; and
Z is H or D, provided that the abundance of deuterium in Z is at least 30%; and
the second therapeutic agent comprises sorafenib, OMP-54F28, trametinib, TRC 105, tremelimumab, tivozanib, glass microspheres containing radioactive yttrium-90, refametinib, regorafenib, erlotinib, vorinostat, PD-033299, TKM-080301, tivantinib, ramucirumab, DCB-BO1202, LY2875358, galunisertib, erismodegib, cabozantinib, nivolumab, MSC2156119J, temsirolimus, OPB-111077, DCR-MYC, CC-223, donafenib, INC280, CC-122, oprozomib, CF102, SGI-110, artesunate, dalantercept, lenvatinib, colchicine, metformin, pentamidine, or a pharmaceutically acceptable salt thereof, and
(d) a method of treating a disorder selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, systemic lupus erythematosus, chronic kidney disease, asthma, chronic obstructive pulmonary disease, neuropathic pain, diabetic neuropathy, fibromyalgia, ulcerative colitis, and arthritis, comprising administering to a patient in need thereof a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess and (ii) a second therapeutic agent, to treat the disorder; wherein Formula I is represented by:
or a pharmaceutically acceptable salt thereof, wherein:
A1, A2, A3, and A4 are independently —C(R9)(R10)—;
A5 is —C(R11)(R12)(R13);
R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D; and
Z is H or D, provided that the abundance of deuterium in Z is at least 30%.

### Claim 55 (depends on 54)

The method of claim 54, wherein the method is method (d).

### Claim 56 (depends on 55)

The method of claim 55, wherein the disorder is chronic kidney disease, and the second therapeutic agent comprises a statin, a diuretic, a non-steroidal anti-inflammatory agent, Vitamin D, a calcium supplement, dialysis, or erythropoietin.

### Claim 57 (depends on 51)

The method of claim 51, wherein the deuterium-enriched compound is administered orally.

### Claim 58 (depends on 51)

The method of claim 51, wherein R1, R2, R3, R4, R5, R6, R7, and R are H; A1, A2, A3, and A4 are —CH2—; and A5 is CH3.

### Claim 59 (depends on 51)

The method of claim 51, wherein the compound is a compound of Formula I-A having an optical purity of at least 75% enantiomeric excess, wherein Formula I-A1 is represented by:
or a pharmaceutically acceptable salt thereof, wherein Z is H or D, provided that the abundance of deuterium in Z is at least 30%.

### Claim 60 (depends on 59)

The method of claim 59, wherein the deuterium-enriched compound is in the form of a pharmaceutically acceptable salt.

### Claim 61 (depends on 60)

The method of claim 60, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

### Claim 62 (depends on 59)

The method of claim 59, wherein the abundance of deuterium in Z is at least 75%.

### Claim 63 (depends on 59)

The method of claim 59, wherein the abundance of deuterium in Z is at least 90%.

### Claim 64 (depends on 63)

The method of claim 63, wherein the compound has an enantiomeric excess of at least 85%.

### Claim 65 (depends on 63)

The method of claim 63, wherein the compound has an enantiomeric excess of at least 90%.

### Claim 66 (depends on 63)

The method of claim 63, wherein the compound has an enantiomeric excess of at least 95%.

### Claim 67 (depends on 51)

The method of claim 51, wherein the compound is:
or pharmaceutically acceptable salt thereof, each having an optical purity of at least 90% enantiomeric excess.

### Claim 68 (depends on 51)

The method of claim 51, wherein the compound is:
having an optical purity of at least 90% enantiomeric excess.

### Claim 69 (depends on 51)

The method of claim 51, wherein the compound is:
hydrochloride having an optical purity of at least 90% enantiomeric excess.

### Claim 70 (depends on 51)

The method of claim 51, wherein the compound is:
or pharmaceutically acceptable salt thereof, each having an optical purity of at least 95% enantiomeric excess.

### Claim 71 (depends on 51)

The method of claim 51, wherein the compound is:
having an optical purity of at least 95% enantiomeric excess.

### Claim 72 (depends on 51)

The method of claim 51, wherein the compound is:
hydrochloride having an optical purity of at least 95% enantiomeric excess.
